Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 86 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: tumor-pulsed dendritic cells Clear all
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Malignant Glioma

NCT00612001
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 3, 2026, 6:41 PM EDT
Terminated Phase 1 Interventional

Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)

NCT03396575
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
Interventions
TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Dose-Intensified TMZ, Td vaccine, Autologous Hematopoietic Stem Cells (HSC)
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
3 Years to 30 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 3, 2026, 6:41 PM EDT
Completed Phase 2 Interventional

A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation

NCT00405327
View directory record Official record
Conditions
Sarcoma, Neuroblastoma, Wilm's Tumor
Interventions
Tumor lysate-pulsed dendritic cell (DC) vaccine, Hematopoietic stem cell transplantation (HSCT)
Biological · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Up to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 3, 2026, 6:41 PM EDT
Completed Phase 3 Interventional

Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin's Lymphoma

NCT00006434
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
tumor-pulsed dendritic cells
Biological
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
10 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 3, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional

DC Vaccine for Patients With Ductal Carcinoma In Situ

NCT02061332
View directory record Official record
Conditions
Breast Cancer, DCIS
Interventions
HER-2 Pulsed Dendritic cell Vaccine
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 3, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.

NCT00289341
View directory record Official record
Conditions
Prostate Cancer
Interventions
vaccine vehicle only, DC/LNCaP
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 3, 2026, 6:41 PM EDT
Completed Phase 1 Interventional

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

NCT04201873
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Dendritic Cell Tumor Cell Lysate Vaccine, Pembrolizumab, Placebo Administration, Poly ICLC
Biological · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 3, 2026, 6:41 PM EDT
Completed Phase 1 Interventional

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

NCT00124124
View directory record Official record
Conditions
Melanoma
Interventions
KLH; Peptides; Dendritic Cells, KLH, peptides plus Montanide
Drug
Lead sponsor
Dr. Nina Bhardwaj
Individual
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2015 · Synced Oct 3, 2026, 6:41 PM EDT
Terminated Phase 1 Interventional

RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.

NCT04963413
View directory record Official record
Conditions
Glioblastoma
Interventions
Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
Biological
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 3, 2026, 6:41 PM EDT
Terminated Phase 2 Interventional Results available

Dendritic Cells (DC) Vaccine for Metastatic Melanoma

NCT01042366
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Vaccination
Biological
Lead sponsor
John Kirkwood
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 3, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional

Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer

NCT00003433
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
carcinoembryonic antigen RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 3, 2026, 6:41 PM EDT
Terminated Phase 1 Interventional

Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer

NCT00003434
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
carcinoembryonic antigen peptide 1, hepatitis B antigen peptide
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 3, 2026, 6:41 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

NCT00019084
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions
aldesleukin, mutant p53 peptide pulsed dendritic cell vaccine, ras peptide cancer vaccine, sargramostim, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 3, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)

NCT01280552
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
ICT-107, Placebo DC
Biological
Lead sponsor
Precision Life Sciences Group
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
25
States / cities
South Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 3, 2026, 6:41 PM EDT
Terminated Phase 1 Interventional

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT

NCT04679194
View directory record Official record
Conditions
AML/MDS
Interventions
Mana 312
Biological
Lead sponsor
Mana Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Denver, Colorado • Atlanta, Georgia • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 3, 2026, 6:41 PM EDT
Available No phase listed Expanded access

Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221

NCT02146066
View directory record Official record
Conditions
GBM, Glioblastoma Multiforme
Interventions
DCVax-L
Biological
Lead sponsor
Northwest Biotherapeutics
Industry
Eligibility
18 Years to 70 Years
U.S. locations
27
States / cities
Little Rock, Arkansas • Los Angeles, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 3, 2026, 6:41 PM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer

NCT00972309
View directory record Official record
Conditions
Prostate Specific Antigens, Prostate Neoplasms
Interventions
T-cell receptor alternate reading frame protein (TARP) peptide vaccine, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 3, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy in Treating Patients With Liver Cancer

NCT00022334
View directory record Official record
Conditions
Liver Cancer
Interventions
AFP
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 3, 2026, 6:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

NCT02224599
View directory record Official record
Conditions
Progressive Solid Malignancies, Refractory Solid Malignancies, Cancer
Interventions
TAPA-pulsed DC vaccine, Cyclophosphamide Pill, Imiquimod Topical Cream
Biological · Drug
Lead sponsor
Kiromic BioPharma Inc.
Industry
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 3, 2026, 6:41 PM EDT
Terminated Phase 1Phase 2 Interventional

Immunotherapy in Treating Patients With Metastatic Breast Cancer

NCT00003432
View directory record Official record
Conditions
Breast Cancer
Interventions
carcinoembryonic antigen RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 3, 2026, 6:41 PM EDT
Withdrawn Phase 1 Interventional

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

NCT05457959
View directory record Official record
Conditions
Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions
Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis, Nivolumab, Placebo Administration, Poly ICLC, Resection
Biological · Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
13 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 3, 2026, 6:41 PM EDT
Terminated Phase 2 Interventional

Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine

NCT00176761
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Interleukin-2 (IL-2)
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Oct 3, 2026, 6:41 PM EDT
Completed Phase 1 Interventional

HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy

NCT02061423
View directory record Official record
Conditions
Breast Cancer
Interventions
HER-2 pulsed Dendritic Cell Vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 3, 2026, 6:41 PM EDT
Recruiting Phase 2 Interventional

Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD

NCT07694986
View directory record Official record
Conditions
Breast Cancer, Leptomeningeal Disease
Interventions
cDC1 Vaccine, Trastuzumab, Nivolumab
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 3, 2026, 6:41 PM EDT